Highly trained neurologists at Riley Children’s Health use the latest tools and therapies to diagnose and treat the most complex neurologic disorders in children. Our team—21 pediatric neurologists, seven advanced practice providers and two genetic counselors—manages numerous specialized multidisciplinary services, including programs for muscular dystrophy and refractory epilepsy. NEUROLOGY
RESEARCH HIGHLIGHTS
■ Translational epilepsy research to identify molecular targets for novel treatments ■ Testing of a novel seizure detection device that also monitors EKG, respiration and pulse oximetry ■ Translational research grant to study the effects of new migraine therapies on bone health ■ Clinical trials – Next generation migraine therapies in adolescents – Spinal muscular atrophy and muscular dystrophies ■ Evaluation of cholinergic markers in children with and without autism and Fragile X syndrome
TOP DISTINCTIONS
Premier programs
Neuromuscular Center Comprehensive
Novel procedures and advanced technologies A case conducted at Riley Children’s suggests that minimally invasive magnetic resonance-guided laser interstitial thermal therapy corpus callosotomy can be successfully used to lateralize the epileptogenic zone in frontal lobe epilepsy. > Learn more. The EEG laboratory and the long-term EEG monitoring program at Riley Children’s are accredited by ABRET Neurodiagnostic Credentialing and Accreditation. most advanced medical and surgical treatment options such as laser ablation, surgical resection, neuromodulation and personalized treatment based on genetic testing. Comprehensive Epilepsy Program Only Level 4 Pediatric Epilepsy Center in Indiana; offers leading- edge diagnostic modalities, including MEG, and the
■ Muscular Dystrophy Association Care Center, recognizing clinical care and research; Parent Project Muscular Dystrophy Certified Duchenne Care Center ■ One of the few centers in the nation performing gene therapy for Duchenne muscular dystrophy and spinal muscular atrophy ■ Accredited by the National Association of Epilepsy Centers as a Level 4 epilepsy center ■ One of the few centers in the Midwest to offer magnetoencephalography (MEG)
multidisciplinary program for patients with nerve and muscle diseases; provides care coordination both to ensure optimal outcomes and facilitate access to leading- edge medical and genetic treatments.
In 2024, Riley Children’s joined the Pediatric Epilepsy Research Consortium , a collaboration of more than 90 leading pediatric epilepsy programs nationwide.
NOTABLE PUBLICATIONS
NeuroNICU Program Indiana’s only neonatal
neurocritical care program; follows infants from the NICU to age 3, with diagnoses that include hypoxic- ischemic encephalopathy, intraventricular hemorrhage of prematurity, neonatal seizures, hydrocephalus, neonatal stroke, brain malformations and hypotonia; also an integral part of the Fetal Center. Pediatric Headache Center Multispecialty program dedicated to the diagnosis and longitudinal care of patients with complex and refractory headache disorders; offers botulinum toxin, nerve blocks and next-generation therapies; active in leading-edge research involving novel therapies and their use in pediatrics.
Neurology: April 2024 A cross-sectional analysis of change in management with evoked potentials: Considering study characteristics can suggest consistent changes International Journal of Molecular Sciences: September 2024 High diagnostic yield and clinical utility of next-generation sequencing in children with epilepsy and neurodevelopmental delays: A retrospective study NeuroSci: July 2024 Unveiling the immediate impact of Prechtl’s general movement assessment training on inter-rater reliability and cerebral palsy prediction Epilepsy and Behavior: December 2024 The long-term effects of limbic non-convulsive status epilepticus in peri-adolescent rats Molecular Therapy: August 2024 Clinical perspectives: Treating spinal muscular atrophy
■ Member of a unique clinical program for patients with
Pelizaeus-Merzbacher disease; clinic held yearly for patients from across the U.S.
■ Pompe disease program offering genetics and physical therapy
DIRECTOR Christopher T. Jackman, MD Associate Professor of Clinical Neurology, IU School of Medicine > Connect with Dr. Jackman on Doximity.
OUR TEAM ALSO PUBLISHED IN: Journal of Child Neurology Ageing Research Reviews
21 board certified physicians
See full team member list >
Annual Report 2024 – 2025
Refer a patient online
317.948.7450
Made with FlippingBook flipbook maker